ArticleNature communications2026
Synthesis of sialylated human milk oligosaccharides by automated glycan assembly.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sialic acids cap the ends of many glycan chains and play pivotal roles in cell signaling, immunity, and pathogen interactions. However, the fast synthesis of sialylated glycans by automated glycan assembly (AGA) has remained a long-standing challenge. Here we show a general strategy that leverages macrobicyclic sialic acid building blocks to achieve reliable α(2,3)- and α(2,6)-sialylation on solid support. Using this method, a collection of nine sialylated human milk oligosaccharides (HMOs) is assembled, including fucosyldisialyllacto-N-tetraose (DSLNF II), a highly branched, fucosylated structure that is very difficult to synthesize by solution-phase methods. An improved global deprotection protocol provides access to pure, functionalized complex glycans suitable for further biological studies. This work provides the broadly applicable solution for automated chemical sialylation, opening the door to prepare collections of sialylated glycans for biomedical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.